Plain language summaries (PLS), also known as lay summaries and trial results summaries, educate participants and the public
about clinical trial results in an easy-to-understand manner. Creating a PLS involves translating complex, technical information from regulatory documents into a short summary using non-promotional and unbiased language. These summaries are generally written at a 6th-to-8th-grade US reading level and avoid medical terminology and industry jargon. Current challenges sponsors face include the creation of a consistent and transparent PLS portfolio that revolves around the development of a reliable template. This template should consider both regulatory requirements and patient-centric health literacy principles that increase understanding. Sponsors preparing to meet short deadlines for PLS submission can incorporate best practices and implementation strategies presented in this white paper that allow for PLS drafting ahead of clinical study report (CSR) finalization.
Explore related content and topics
Blog
How COVID-19 Has Impacted Regulatory Operations: A Conversation with PRA’s Regulatory Operations Team
COVID-19 impacted all areas of our lives over the past year. We caught up with the Regulatory Operations team to see how working from home,…
Blog
Navigating Global Regulatory CMC Processes During Public Health Crises
Chemistry, manufacturing, and controls (CMC) regulations are a critical part of the drug development path and the ongoing production and distribution…
White Paper
Clinical Trial Disclosure - Requirements & Strategy Considerations within Clinical Trial Transparency
Clinical Trial Disclosure (CTD) is a compliance requirement mandated by various national laws and policies, and is at the heart of a paradigm shift…